Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire

Contributed by: Business Wire

Logo

Tags

Biotechnology

Pharmaceutical

Health

Irish Revenue

More Like This

Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

Takeda Announces New Assignments of Directors

Takeda Announces Chief Financial Officer Succession